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Reporting of Patient-Reported Outcomes in Randomized Trials:A recent article in JAMA [1] reports the extension of the Con-
solidated Standards of Reporting Trials (CONSORT) Patient-
Reported Outcome (PRO) group on recommendations for what
should be included when reporting the results of PROs in
randomized controlled trials (RCTs) as primary or secondary
outcomes. Five CONSORT PRO checklist items are recommended
as follows:○ that PROS be identiﬁed as a primary or secondary outcome in
the abstract;○ that a description of the hypothesis of PROs and relevant
domains be provided (i.e., if a multidimensional PRO tool has
been used);○ that evidence of the PRO instrument’s validity and reliability
be provided or cited;○ that statistical approaches for dealing with missing data be
explicitly stated; and○ that PRO-speciﬁc limitation of study ﬁndings and general-
izability of results to other populations and clinical practice be
discussed.
PRO extension was deemed unnecessary for many CONSORT
checklist items.
These recommendations are important for editors, reviewers,
and readers of Value in Health (VIH). VIH may report PRO ﬁndings
separate from the main results of the RCT, which are often found
in journals targeted to clinicians. These recommendations also
hold implications for ISPOR members in the documentation of
study protocols, statistical analysis plans, and other elements of
RCTs. Special attention can be given to these checklist items on
PROs when developing sources of documentation for PRO out-
comes used in the trial or analyses of PROs presented in
trial data.
PROs in this Consort Extension refer to outcomes labeled as
health status, health-related quality of life, symptoms, utilities, satisfac-
tion with care, and adherence. This wide-ranging deﬁnition is
particularly relevant to the ISPOR audience because some of
these concepts may not be part of current medical product
regulatory review or labeling or considered in reviews by reim-
bursement authorities. The Extension requests that the rationale
for including each PRO and its constituent parts or domains be
presented along with hypotheses. This rationale is often impor-
tant in the selection of preference-based or utility measures as
well as other PROs frequently used by ISPOR members and seen
in VIH. The recommendations point to sometimes-neglected
aspects of data collection and analysis, such as mode ofial support: The author has no other ﬁnancial relaadministration, use of any proxy reporting, loss to follow-up,
and methods used to account for missing data.
Of major importance is the recommendation that inter-
pretation of PRO results be made in relation to clinical out-
comes, including survival data. PRO end points used in clinical
trials may not always be closely associated with clinical
outcomes or survival, because different concepts are being
measured or an important clinical measure, such as lung
function, may not be associated with changes in symptoms,
behaviors, or other outcomes more distal in impact. None-
theless, patients, families, and other stakeholders are inter-
ested in considering the beneﬁts and harms seen in both
clinical and PRO outcomes. Interpretation of trial results may
be incomplete without all outcomes that are patient-
important. Distinctions in this Extension are made between
primary and secondary outcomes or key secondary outcomes,
particularly when the sample size is taken into account or
alpha is spent in statistical analysis of these PRO outcomes.
This distinction is familiar to the ISPOR audience where end
point models and statistical analyses of trial data are often-
considered topics.
This CONSORT extension does not currently apply to
other clinical outcome assessments. These include, in addition
to PROs, clinician-reported outcomes or observer-reported
outcomes [2]. Nevertheless, the same principles may apply
to these outcomes. CONSORT and its extensions are “living
documents,” and further consideration may be given to
the full range of clinical outcome assessments as more and
more trial publications use these outcomes in different
combinations.
This CONSORT extension provides additional instructions to
authors preparing journal submissions, including presentation of
technical material in appendices when space limitations prohibit
this in the source article. VIH has the important policy to include
such appendices for technical material [3]. The PRO extension
recommendation could well ﬁnd a place in modiﬁed instructions
to VIH contributors.Acknowledgments
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